Listen to Gynecologic Oncology

Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?

Hosted by:
Warner Huh, MD, Deputy Editor of Gynecologic Oncology
Featuring:
Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of America
Ramez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA

Editor’s Choice Paper:
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma

Editorial:
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer

Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology

Featuring:
Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical College
Gretchen Glaser, MD, Mayo Clinic
John Weroha, MD, Mayo Clinic

Editor’s Choice Papers: 

What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women

Editorial:  Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approach

Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology


Featuring:
Ann Oluloro, MD, MPH, University of Washington
Eloise Chapman-Davis, MD, Weill Cornell Medicine

 
 
 
 

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer